4 Results for "

BGB-283

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "BGB-283" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-18957
CAS No.: 1446090-79-4
Synonyms: BGB-283
Target:  

EGFR Raf

Research Areas:  

Cancer

Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRaf V600E and EGFR, respectively.
loading...
    loading...
Cat. No.: HY-18957B
CAS No.: 1854985-74-2
Synonyms: BGB-283 maleate
Target:  

EGFR Raf

Research Areas:  

Others Cancer

Lifirafenib (BGB-283) maleate is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRaf V600E and EGFR, respectively .
loading...
    loading...
Cat. No.: HY-18957C
CAS No.: 2025320-97-0
Synonyms: BGB-283 hydrochloride
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

Lifirafenib hydrochloride (BGB-283 hydrochloride) is a novel, reversible B-RAFV600E inhibitor with antitumor activity. Lifirafenib has shown potent antitumor activity against solid tumors with B-RAFV600E mutations, such as melanoma, thyroid cancer, and low-grade serous ovarian cancer. Lifirafenib exhibits selective cytotoxicity in vitro, preferentially inhibiting the proliferation of cancer cells with B-RAFV600E and EGFR mutations/amplification. Lifirafenib can achieve dose-dependent inhibition of tumor growth in animal models, accompanied by partial and complete tumor shrinkage .
loading...
    loading...
Cat. No.: HY-18957A
CAS No.: 1446090-77-2
Synonyms: rel-BGB-283
Target:  

Raf EGFR

Research Areas:  

Cancer

rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib (HY-18957). Lifirafenib is a potent Raf Kinase and EGFR inhibitor .
loading...
    loading...